Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2024-04-10 Transaction in Own Shar…
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly announces a 'Transaction in Own Shares' detailing the purchase of 140,000 ordinary shares as part of a 'share buyback programme'. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The document is short and contains specific transaction details, confirming it is the primary announcement of this activity, not just a general regulatory filing (RNS).
2024-04-10 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states the subject matter in the title section: "Transaction in Own Shares". It details the purchase of 140,000 ordinary shares by the company as part of a share buyback programme, including the date, price, and resulting treasury share count. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The presence of the RNS Number and the closing statement confirming RNS as the information provider indicates it is a regulatory announcement, but the specific content dictates the POS classification over the general RNS fallback.
2024-04-09 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states the subject is 'Transaction in Own Shares' and details the purchase of 140,000 ordinary shares as part of a 'share buyback programme'. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The presence of the RNS Number and the closing statement referencing RNS confirms it is a regulatory announcement, but the specific content dictates the POS classification over the general RNS fallback.
2024-04-08 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly announces a 'Transaction in Own Shares' as part of a 'share buyback programme'. It details the number of shares purchased, the price, and the resulting change in the total voting rights. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The presence of the RNS Number and the closing statement confirming the information is provided by RNS suggests it is a regulatory announcement, but the specific content dictates the POS classification over the general RNS fallback.
2024-04-05 English
Achilles reports full year 2023 Financial Results
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement released by Syncona Limited on April 4, 2024. The primary purpose of this announcement is to relay the 'full year 2023 Financial Results' of its portfolio company, Achilles Therapeutics plc, and to state that the full text of Achilles' announcement is contained below. The document includes the full text of Achilles' earnings release, which details financial highlights for the year ended December 31, 2023, including the Consolidated Balance Sheets. Because this document is an announcement *about* another company's financial results, and it is distributed via the RNS system, it fits the definition of a general regulatory announcement or a report publication announcement. Since the document itself is the announcement relaying the results (not the primary 10-K or IR filing from Achilles), and it is distributed via RNS, the most appropriate classification is RNS, as it is a regulatory news service filing relaying information. It is not the comprehensive Annual Report (10-K) or the standalone Audit Report (AR). It is also not strictly an Earnings Release (ER) because it is a secondary announcement relaying the primary ER of a portfolio company, making RNS the best fit for this specific filing format.
2024-04-04 English
Achilles provides clinical data update
Regulatory Filings Classification · 98% confidence The document is an RNS announcement (indicated by 'RNS Number : 3471J' and the footer referencing RNS, the news service of the London Stock Exchange). The content is an update provided by Syncona Limited regarding clinical data from its portfolio company, Achilles Therapeutics, concerning ongoing Phase I/IIa trials. This is a general regulatory announcement concerning portfolio company progress, not a comprehensive annual report (10-K), a formal earnings release (ER), or a specific management/board change (MANG). Since it is a general regulatory news service announcement that doesn't fit neatly into the other specific categories (like DIV, CAP, or DIRS), the most appropriate classification is the general regulatory filing category.
2024-04-04 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.